Multi-kinase inhibitors including sorafenib and lenvatinib were the first-line systemic treatment options for unresectable hepatocellular carcinoma (uHCC) patients, albeit with a median overall survival (OS) of around 1 year.¹ Following the regulatory approval based on the significant OS improvement in 2020, atezolizumab + bevacizumab (atezo/bev) became a new and current standard of care (SoC) for uHCC.¹ Despite the tremendous advancement, additional systemic treatment options with long-term efficacy and well tolerated safety profiles are still warranted to cater for individual medical needs of uHCC patients.² Very recently, a novel immunotherapy (IO) combination (i.e., the STRIDE regimen) featuring a single high-priming dose of tremelimumab (TREME) [an anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)] and every-4-week durvalumab (DUR) (anti-PD-L1) showed encouraging clinical efficacy and high tolerability in a phase 3 trial, becoming the latest addition to the armamentarium of first-line systemic treatment options for uHCC patients.² In the 4^th AGM and HBP workshop organized by the Hong Kong Stereotactic Body Radiation Therapy (SBRT) Study Group, Professor Arndt Vogel and Dr. Chiang, Chi-Leung presented new data and discussed the latest advancement in the rapidly evolving treatment landscape of uHCC. Subsequently in an interview with Omnihealth Practice, Dr. Chiang shared his insights into the new dual IO treatment option in uHCC. He also provided updates on the ongoing study START-FIT [transarterial chemoembolization (TACE) + SBRT + dual IO] with promising early results. At the end of the interview, he shared a clinical case which demonstrated the remarkable efficacy of SBRT + dual IO in a local uHCC patient

Cervical cancer (CC) is the 4th most common female cancer globally, claiming more than 300,000 women’s lives in 2018.1 In Hong Kong, the incidence of CC remained high at around 7 per 100,000 women in 2019, which was still below the World Health Organization’s (WHO) target of fewer than 4 per 100,000